Palantir and the NHS (No. 2)

That this House notes that Members of the Science, Innovation and Technology Committee, the Health and Social Care Select Committee, and other hon. Members have raised serious concerns regarding the procurement, trust, operation and long-term implications of the Federated Data Platform (FDP) contract with Palantir; is concerned that key components remain under supplier control, and that the contract’s subscription model leaves the NHS without real ownership; acknowledges that a credible, funded, and time-bound exit and transition strategy is essential to safeguard patient services, value for money, and continuity of critical data infrastructure; recognises the risks of vendor lock-in, potential price gouging under a single supplier, and that placing critical national health data infrastructure in the hands of a foreign-controlled proprietary provider raises serious digital sovereignty concerns, including the potential exposure of UK data to foreign legal powers; further notes reports of sustained dissatisfaction among the clinicians, and NHS staff regarding usability and effectiveness, and further notes recent analysis in the BMJ raising concerns about transparency, governance and the adequacy of accountability arrangements surrounding the FDP; calls on the Government to ensure that local need, clinical judgement and value for money are the top priorities for decisions on implementing the FDP, not top-down requirements through the medium-term planning framework; and further calls on the Government to ensure there is timely contingency, and scrutiny, with all necessary information available, to deliver an exit from Palantir, to an open, interoperable and sovereign alternative.